Bedrocan Cannabis Corp. – tsx.v: BED
Bedrocan is the most experienced, research-centered producer of pharmaceutical-grade medicinal cannabis in the world, with a mission to provide patients and healthcare professionals with safe, effective and consistent medicine for the appropriate management of diagnosed health conditions.
Bedrocan is the global leader in medicinal cannabis. The company’s strains of pharmaceutical cannabis have been used by more than 15,000 patients in seven countries, including Canada.
Bedrocan has been supplying government-regulated medicinal cannabis for 13 years, to patients with conditions including:
• Chronic pain
• Multiple sclerosis
• Anxiety and depression
• Crohn’s disease
• And multiple other medical conditions
Proven Track Record
No medicinal cannabis company in Canada has more experience or participation in medical research.
• More than a decade of experience supplying pharmaceutical cannabis under the authority of the Dutch Ministry of Health, Welfare and Sport
• Committed to clinical research and ISO 9001-rated production processes and product development, on an international scale
• A trusted source of unbiased information regarding the safe and effective use of medical cannabis for Canadian patients and health professionals
• Global leader in medicinal cannabis research and product innovation
• Only source of legally-exported cannabis in the world
• Only company to develop placebo versions of its medicinal cannabis strains, for use in clinical studies
Quality, Focus and Consistency
• QUALITY: The most rigorous production and product quality standards in the world, meeting and exceeding government requirements in seven countries, including Canada
• FOCUS: Five strains developed to meet the therapeutic needs of patients
• CONSISTENCY: Pharmaceutically consistent product characteristics, predictability and cannabinoid content across all strains
• Bedrocan is one of only two companies currently supplying pharmaceutical-grade medicinal cannabis.
• Pharmaceutical-grade cannabis has a standardized chemical composition, and meets the accepted contaminant levels for medicines that are inhaled. Both standards go beyond the requirements of Health Canada.
• Bedrocan has over 13 years of experience producing pharmaceutical-grade cannabis. Our production is ISO 9001:2008 certified. We have a validated, standardized process of producing pharmaceutical-grade cannabis.
• Bedrocan is the only company in the world with of the ability to produce genetically distinct, pharmaceutical-grade cannabis strains, provided in bud form.
Benefits and Risks
There is now a considerable body of clinical research demonstrating the therapeutic benefits of pharmaceutical cannabis/cannabinoids in managing different health conditions. However, it is critical to note that:
• Medicinal cannabis is not a cure for any known disease. A growing body of research has shown it to alleviate specific symptoms of certain conditions, thereby improving patients’ quality of life and ability to function.
• As with any prescription or non-prescription medicine, and depending on how medicinal cannabis is consumed, there are risks and side effects as well as benefits. Consumers must be provided with all the facts, so they can make an informed decision together with their physician.
click here to learn more about the risks and benefits associated with medicinal cannabis
Risks of Non-Pharmaceutical Cannabis
All cannabis is not the same. Bedrocan’s products are produced according to pharmaceutical-grade – the highest quality assurance standard for cannabis. Health Canada does not require all Licensed Producers to be of pharmaceutical-grade quality.
Bedrocan’s production facilities are ISO-9001:2008 certified and the entire production procedure is described in Standard Operating Procedures. Bedrocan follows the guidelines of Good Agricultural Practice (GAP) as well as Good Production Practices (GPP). The quality and safety of the final products are guaranteed through mandatory testing by certified independent laboratories. As a result, Bedrocan products are guaranteed to be free of pesticides, agricultural chemicals, heavy metals, or bacteria or molds.
That is not the case with other sources of cannabis. Research in multiple countries has found that non-pharmaceutical cannabis commonly contains contaminants and toxins including mold, bacteria, pesticides, heavy metals and insect parts, and even harmful adulterants added to increase weight.
click here for a list of studies about the risks of contaminants in cannabis
Bedrocan strives to develop and deliver the full medical potential of the cannabis plant to those in need worldwide.
To be a bridge between patients’ needs for cannabis and the quality standards of modern medicine.
Our Core Values
Our business activities are supported by licenses and standardized procedures that are in full compliance with the laws and regulations at every applicable level.
Commitment to Science
Our work is evidence-based and grounded in science. From cultivation techniques and developing new varieties, to clinical trials and studying patient preferences, advancing the scientific understanding of cannabis is the core of our work. We initiate our own research projects, pursue collaborations, and supply the tools for studies by independent scientists.
We are committed to social, environmental, and economic sustainability.
- Social – We strive to foster a good quality of life for our employees and provide an open and accountable governance structure. Through education and engagement with the communities where we work, we promote connectedness and fairness among all stakeholders.
- Environmental – We work to go above and beyond the highest environmental standards out of respect and consideration for our local and global communities. We use renewable energy sources, minimize product input, and recycle where we can.
- Economic – We are focused on responsible, sustainable economic growth. Wherever possible, we strive to produce our products locally, strengthening the workforce and the bio-based economy of the region.
We believe in open and respectful communication within our company and with our patients and stakeholders. All opinions have value, and we believe that dialogue and communication lead to cooperation and trust. Patients’ perspectives are important to us. In addition, people have a right to know about our work. We are always open to questions and comments, and encourage interaction with the public.
To us, quality means adhering to the highest regulatory standards for producing pharmaceutical plant products while respecting the expectations of users of our products. We breed our varieties to meet the needs of patients and healthcare professionals. We take great care in plant cultivation and processing. Our products have a consistent composition and meet Health Canada’s requirements to be free from contamination, including pesticides, mold, bacteria, and heavy metals.
In 2011, Bedrocan BV, a Dutch company, was invited to Ottawa by Health Canada to comment on Canada’s new regulations for medicinal cannabis, the Marijuana for Medical Purposes Regulations (MMPR). Since the Netherlands has an established medicinal cannabis framework, we came away from this meeting with a sense that Canadian producers, patients, and healthcare professionals could benefit from the knowledge and experience Bedrocan BV had developed producing medicinal cannabis in Europe. We decided to look more closely into how we could provide Canadians access to high quality standardized medicinal cannabis. This led to our decision to work with Canadian management to establish a company in Canada to work under the newly established regulatory (MMPR) framework.
Bedrocan Canada is a joint venture between “Bedrocan BV” of the Netherlands and “Bedrocan Canada Inc”, a Canadian start-up with extensive knowledge and experience in the use of cannabis and cannabinoids in clinical practice.
Bedrocan Canada will contribute to the needs of Canadian patients by providing access to our varieties of standardized medicinal cannabis under a federally regulated environment, and by using science to address the real concerns of Canadian patients and health care practitioners. Bedrocan is about raising the expectations of what it means for cannabis to be truly “medicinal.” In this way, we will work together to bridge the gap with science to better serve the needs of patients and meet the regulatory demands of modern medicine.
History in Europe
For over 10 years, Bedrocan BV has worked with universities, industry, government, and NGO partners in the Netherlands and around the world to conduct the genetic, botanical, chemical, and social research necessary to help cannabis meet the regulatory demands of modern medicine.
Bedrocan BV has its roots in the North of the Netherlands, an area with a long history of agricultural achievements. Founded in 1984, we first specialized in the indoor, standardized growth of vegetables and herbs. It wasn’t until the late 1990′s when we began our first experiments in growing medicinal-grade cannabis under federal license.
In 1998, the Dutch Minister of Health, Welfare and Sport noticed patients purchasing cannabis from popularly known “coffeeshops”, where recreational use has been tolerated since the 1970′s. The Minister was concerned over the lack of quality control, and believed the “bar” atmosphere did not serve the medical needs of patients. In response, she proposed an official program whereby pharmaceutical-grade cannabis could be prescribed by doctors and dispensed through pharmacies.
In 2003, after a thorough screening by Dutch authorities, Bedrocan BV was contracted by the Dutch Ministry of Health’s newly-formed Office of Medicinal Cannabis (OMC) to produce different strains for patients and researchers. Other European countries soon created similar programs and requested a regular supply of cannabis from the only source in Europe that met the required medical standards.
Today, the Dutch government remains the only source in the world for medicinal-grade cannabis that is exported for patient use in full compliance with international laws and regulations.
Marc Wayne – Chief Executive Officer
Board Chairman for the Canadian Medicinal Cannabis Industry Association (CMCIA) – membership for licensed producers and applicants. Formerly the Director of Business Development for the Canadian Consortium for the Investigation of Cannabinoids (CCIC), a leading organization of scientists and healthcare professionals established to promote evidenced based research and medical education concerning the therapeutic application of cannabis and cannabinoid-based medicines. Previous to his work in the cannabinoid space, Marc was managing partner and founder of the OAM Computer Group, a leading Canadian integrator and founding investor and Board member of Lasoo.com a leading provider of spatial software ASP services, whose technology was purchased by Yahoo (2000-2001).
Michael Singer – Chief Financial Officer
Michael is an accomplished pharmaceutical industry executive and consultant and he currently chairs the Board of Directors of Warnex Inc. (TSX-V: WNX.H). Previously, he was Chief Financial Officer and Corporate Secretary of Thallion Pharmaceuticals Inc. from 2007 until its sale to BELLUS Health Inc. in 2013. Prior to Thallion, he served as Chief Financial Officer of Caprion Pharmaceuticals Inc. from 2000 until its merger with Ecopia BioSciences Inc. to form Thallion in 2007. Michael graduated from McGill University (1991) and is a Certified Professional Accountant – Certified General Accountant with the Ordre des CPA du Québec.
Tjalling Erkelens – Chief Production Officer
Founder and Chief Executive Officer of Bedrocan BV. For the past 20 years, Tjalling has developed and standardized unique methods of producing cannabis to pharmaceutical standards to a level achieved by no other company in the world.
Under Tjalling’s leadership, Bedrocan has become the only company in the world whose cannabis is exported for patient use in full compliance with the Single Convention on Narcotic Drugs (1961). Bedrocan supplies cannabis to patients in Germany, Italy, Finland and Norway, and soon Switzerland and the Czech Republic, and to researchers around the world.
Tjalling is a member of the Advisory Committee on Applied Horticulture of the University of Wageningen’s Health and Plant Division, The Netherlands.
H. Hamish Sutherland – Chief Operating Officer
A hands on team builder, marketing and operations executive with experience growing start-ups across three continents. Hamish built the Asia Pacific operations for Bid.Com (in Melbourne, Australia) as President and Managing Director of Bid.com Pty Ltd. He established the international server operations, and sales and marketing teams in Japan, South Africa, India, Australia and Hong Kong. Hamish has been responsible for founding the operations of 17 offshore companies entering North America for the first time, including Mincom, Vulcan Software and Whittle. Hamish facilitated $100 million of direct investment and acquisitions between Australian and Canadian companies. He was a founding limited partner and Board Member for the Upper Canada Brewing Company.
Hamish is a Professional Engineer in Ontario and is the active Chair of the Little Geeks Foundation.
Dr. Arno Hazecamp – Advisor, R&D and Education
Dr. Arno Hazekamp is the Head of Research and Education of Bedrocan BV, the only licensed producer of pharmaceutical-quality cannabis for the Dutch Health Ministry. He is the author of numerous scientific papers on cannabis chemistry, delivery mechanisms, quality control and patient surveys. As an international authority on biochemical cannabis research, he is considered one of the foremost researchers in the field.
Dr. Hazekamp was actively involved in creating quality standards used by the Dutch Government, and was a co-founder of the non-governmental organization (NGO) NCSM, intended to inform physicians and patients of the proper use of cannabis in clinical practice. Member of the Board of International Association for Cannabis as Medicine (IACM) since 2009.
In 2007, Arno started a phytochemical contract laboratory, making a wide range of highly pure cannabinoid standards commercially available to researchers worldwide. He was also involved in the early phase of Echo Pharmaceuticals, a Dutch pharmaceutical company developing a sublingual administration form of THC and other cannabinoids.
Barry Fishman – Board Advisor
Barry is a recognized health care leader and driver of profitable growth, through strategic leadership, operational effectiveness, team development and financial management.
Up to the end of 2013, Barry was President & CEO of Teva Canada, where during his tenure, increased operating profit and market share by over 70%. Teva Canada is a leading pharmaceutical company with up to $1B in revenue and almost 2000 employees.
As CEO of Taro Canada, a small specialty pharmaceutical company, Barry tripled sales, strengthened talent, improved profitability and entered new untapped markets. Prior to Taro, Barry spent 17 years with Eli Lilly Canada where he advanced through several cross-functional leadership roles, including Vice President of Marketing.
Barry is married to Lynda, an author and inspirational speaker, and sits on several for profit and non-profit Boards.
For more information, visit www.bedrocan.com.